Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche / Genentech’s Zelboraf plus Cotellic, Novartis’s Tafinlar plus Mekinist, and Pfizer / Array BioPharma’s Braftovi plus Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and unresectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. Given the expected label expansion of current therapies and the approval of novel agents such as adoptive cell therapies, therapeutic vaccines, and intralesional therapies, the malignant melanoma treatment paradigm will continue to evolve and contribute to the continued growth of this therapeutic market.

Questions answered

• How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? How will drug treatment rates change over the forecast period?
• What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most prescribed and why?

• Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?

• What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Geography: United States, EU5, Japan

Primary research: 17 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Incidence of malignant melanoma by country, segmented by BRAF mutation status, disease stage, and line of therapy

Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.

• Quantify market potential for your pipeline assets and those of your competitors.

• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.

• Gauge the commercial outlook and impact of key market events.